Heron Therapeutics Inc vs Micron Technology, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Micron Technology, Inc. trades at $1,055 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 17203.4× Heron Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Micron Technology, Inc. for 48 Days on average.
| HRTX | MU | |
|---|---|---|
Market Cap | $68.01M | $1.17T |
Volume | 1,891,941 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $1.49 | $1.21K |
52-Week Low | $0.27 | $181.60 |
Typical Hold Time | 35 Days | 48 Days |
Enterprise Value | $174.75M | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Micron Technology (MU) trades at $1,088, up 4.06% with strong bullish momentum, supported by consecutive earnings beats and robust AI-driven memory demand. The stock shows impressive fundamentals with 63.8% net margins and 91.77% ROE, while technical indicators signal bullish moving averages. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility, though growth deceleration concerns linger.
Outlook remains positive with analyst consensus at $1,590 price target (82.85% buy ratings), but risks include cyclical memory pricing, competitive pressures, and potential AI demand normalization. The stock's valuation appears reasonable with P/E of 13.94, supporting continued upside if execution persists.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →